VHeFT I (hydralazine ISDN), 1986 trial summary    PDF trial summary

A randomised clinical trial investigating the effect of hydralazine-ISDN versus placebo in patienst with chronic congestive heart failure and cardiac dilatation (CT ratio>0.55) or LVEF <45% in association with reduced exercise tolerance

        Z

N Engl J Med 1986;314:1547-52  



Studied treatment hydralazine 300mg/d ISDN 160mg/d
Control treatment placebo



Patients patienst with chronic congestive heart failure and cardiac dilatation (CT ratio>0.55) or LVEF <45% in association with reduced exercise tolerance
Group sizes186 / 273



Blindness double blind Inclusion period march 1980-june 1985
Follow-up duration 2.3 y (range 0.5-5.7 years) Centers
Lost to FU ND geographical localisation
Primary endpoint Design Parallel groups
ArretTrt1ND
PeriodeInclusionmarch 1980-june 1985



EndpointX1N1X0N0TE95% CI cardiac death - 186 - 273 no data All cause death 72 186 120 273 0,88[0,60; 1,29]0,22,01,0

Cohn JN, Archibald DG, Ziesche S, Franciosa JA, Harston WE, Tristani FE, Dunkman WB, Jacobs W, Francis GS, Flohr KH Effect of vasodilator therapy on mortality in chronic congestive heart failure. Results of a Veterans Administration Cooperative Study. N Engl J Med 1986;314:1547-52     [PMID: 3520315]   link to pdf   add to Mendeley  



Registering number (see trial on clinicaltrials.gov)
Code Name

 

All trials of hydralazine-ISDN

Appears in following systematic reviews: